atenolol has been researched along with Aortic Diseases in 9 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Aortic Diseases: Pathological processes involving any part of the AORTA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS)." | 9.17 | Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. ( Chen, CA; Chiu, HH; Chiu, SN; Hu, FC; Lin, MT; Lu, CW; Wang, JK; Wu, MH, 2013) |
| "Efficacy of losartan versus atenolol in the prevention of progressive dilation of the aorta, improved aortic distensibility, and prevention of adverse events (aortic dissection or rupture, cardiovascular surgery, or death) will be assessed in this study." | 6.76 | [Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome]. ( Centeno, J; Cortina, J; Evangelista, A; Forteza, A; García, D; García-Dorado, D; Gutiérrez, L; Rodríguez-Palomares, J; Sánchez, V; Sanz, P; Teixidó, G, 2011) |
| "The Pediatric Heart Network randomized trial of atenolol versus losartan in the Marfan syndrome showed no treatment differences in the rates of aortic-root growth or clinical outcomes." | 5.27 | Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome. ( Bradley, TJ; Campbell, MJ; Chen, S; Cohen, MS; Colan, SD; De Backer, J; Heydarian, H; Hoskoppal, A; Lacro, RV; Lai, WW; Levine, JC; Liou, A; Marcus, E; Nutting, A; Olson, AK; Parra, DA; Pearson, GD; Pierpont, ME; Printz, BF; Pyeritz, RE; Ravekes, W; Roman, MJ; Selamet Tierney, ES; Sharkey, AM; Sleeper, LA; Srivastava, S; Young, L, 2018) |
| "To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS)." | 5.17 | Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. ( Chen, CA; Chiu, HH; Chiu, SN; Hu, FC; Lin, MT; Lu, CW; Wang, JK; Wu, MH, 2013) |
| "The REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study is a randomized, double-blind trial comparing atenolol versus perindopril/indapamide; 375 patients with hypertension, with BP and PWV measurements at baseline and after 12 months of treatment, were divided into 3 tertiles according to baseline PWV and included in a post-hoc analysis." | 5.14 | Blood pressure response under chronic antihypertensive drug therapy: the role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study. ( Achimastos, A; Blacher, J; Protogerou, A; Safar, ME; Stergiou, GS, 2009) |
| "The Pediatric Heart Network is conducting a large international randomized trial to compare aortic root growth and other cardiovascular outcomes in 608 subjects with Marfan syndrome randomized to receive atenolol or losartan for 3 years." | 4.89 | Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome. ( Bradley, TJ; Campbell, MJ; Chen, S; Cohen, MS; Colan, SD; De Backer, J; Guey, LT; Heydarian, H; Lacro, RV; Lai, WW; Levine, JC; Lewin, MB; Marcus, E; Mart, CR; Pearson, GD; Pignatelli, RH; Printz, BF; Selamet Tierney, ES; Sharkey, AM; Shirali, GS; Sleeper, LA; Srivastava, S, 2013) |
| "Efficacy of losartan versus atenolol in the prevention of progressive dilation of the aorta, improved aortic distensibility, and prevention of adverse events (aortic dissection or rupture, cardiovascular surgery, or death) will be assessed in this study." | 2.76 | [Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome]. ( Centeno, J; Cortina, J; Evangelista, A; Forteza, A; García, D; García-Dorado, D; Gutiérrez, L; Rodríguez-Palomares, J; Sánchez, V; Sanz, P; Teixidó, G, 2011) |
| "Aortic stiffness and left ventricular hypertrophy (LVH) are predictors of mortality in hemodialysis (HD) patients." | 2.71 | Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. ( Adda, H; Guerin, AP; London, GM; Marchais, SJ; Metivier, F; Pannier, B, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Flyer, JN | 1 |
| Sleeper, LA | 3 |
| Colan, SD | 3 |
| Singh, MN | 1 |
| Lacro, RV | 3 |
| Selamet Tierney, ES | 2 |
| Levine, JC | 2 |
| Roman, MJ | 1 |
| Bradley, TJ | 2 |
| Chen, S | 2 |
| Campbell, MJ | 2 |
| Cohen, MS | 2 |
| De Backer, J | 2 |
| Heydarian, H | 2 |
| Hoskoppal, A | 1 |
| Lai, WW | 2 |
| Liou, A | 1 |
| Marcus, E | 2 |
| Nutting, A | 1 |
| Olson, AK | 1 |
| Parra, DA | 1 |
| Pearson, GD | 2 |
| Pierpont, ME | 1 |
| Printz, BF | 2 |
| Pyeritz, RE | 1 |
| Ravekes, W | 1 |
| Sharkey, AM | 2 |
| Srivastava, S | 2 |
| Young, L | 1 |
| Guey, LT | 1 |
| Lewin, MB | 1 |
| Mart, CR | 1 |
| Pignatelli, RH | 1 |
| Shirali, GS | 1 |
| Protogerou, A | 1 |
| Blacher, J | 1 |
| Stergiou, GS | 1 |
| Achimastos, A | 1 |
| Safar, ME | 1 |
| Forteza, A | 1 |
| Evangelista, A | 2 |
| Sánchez, V | 1 |
| Teixidó, G | 1 |
| García, D | 1 |
| Sanz, P | 1 |
| Gutiérrez, L | 1 |
| Centeno, J | 1 |
| Rodríguez-Palomares, J | 1 |
| Cortina, J | 1 |
| García-Dorado, D | 1 |
| Goya, M | 1 |
| Alvarez, M | 1 |
| Teixido-Tura, G | 1 |
| Merced, C | 1 |
| Pineda, V | 1 |
| Chiu, HH | 1 |
| Wu, MH | 1 |
| Wang, JK | 1 |
| Lu, CW | 1 |
| Chiu, SN | 1 |
| Chen, CA | 1 |
| Lin, MT | 1 |
| Hu, FC | 1 |
| London, GM | 1 |
| Marchais, SJ | 1 |
| Guerin, AP | 1 |
| Metivier, F | 1 |
| Adda, H | 1 |
| Pannier, B | 1 |
| Pinheiro, BB | 1 |
| Fagundes, WV | 1 |
| Haddad, R | 1 |
| Ramos, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome[NCT00651235] | Phase 2 | 44 participants (Anticipated) | Interventional | 2007-02-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for atenolol and Aortic Diseases
| Article | Year |
|---|---|
Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Analysis of Variance; Angiotensin II Type | 2013 |
5 trials available for atenolol and Aortic Diseases
| Article | Year |
|---|---|
Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome.
Topics: Adolescent; Aorta; Aortic Diseases; Atenolol; Cardiac Imaging Techniques; Child; Child, Preschool; D | 2018 |
Blood pressure response under chronic antihypertensive drug therapy: the role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study.
Topics: Aged; Antihypertensive Agents; Aortic Diseases; Atenolol; Blood Pressure; Double-Blind Method; Drug | 2009 |
[Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome].
Topics: Adolescent; Adult; Antihypertensive Agents; Aorta; Aortic Diseases; Atenolol; Child; Child, Preschoo | 2011 |
Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Aortic | 2013 |
Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients.
Topics: Adult; Antihypertensive Agents; Aortic Diseases; Arteriosclerosis; Atenolol; Blood Pressure; C-React | 2003 |
3 other studies available for atenolol and Aortic Diseases
| Article | Year |
|---|---|
Effect of Losartan or Atenolol on Children and Young Adults With Bicuspid Aortic Valve and Dilated Aorta.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; | 2021 |
Abdominal aortic dilatation during pregnancy in Marfan syndrome.
Topics: Adrenergic beta-Antagonists; Adult; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Atenolol; Ce | 2012 |
[Intramural haematoma of the descending aorta].
Topics: Adrenergic beta-Antagonists; Aorta, Thoracic; Aortic Diseases; Atenolol; Electrocardiography; Female | 2005 |